SPAC combinationJul 20, 2026Completed
🇺🇸 United States
FFreenome Holdings, Inc.PCPerceptive Capital Solutions Corp
Healthcare › Life Science Tools & Diagnostics
Deal valueUndisclosed
AnnouncedJul 20, 2026
ConsiderationUndisclosed
StructureOne-step merger
RegionNorth America
Cross-borderNo
Contingent paymentNo
Overview
Freenome, a blood-based early cancer detection company, entered into a business combination agreement with SPAC Perceptive Capital Solutions Corp. The deal was accompanied by a $240 million PIPE and about $70 million from the trust account.
Deal rationale
The combination gives Freenome about $310 million in gross proceeds to fund its cancer screening portfolio, AI/ML multiomics platform and commercial infrastructure.
AI-generated from the SEC filingCompletedHealthcare › Life Science Tools & DiagnosticsUnited StatesNorth America
Timeline
- AnnouncedJul 20, 2026Filing
Valuation and terms
| Equity value | Undisclosed | |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Undisclosed |
Advisors
Buy-side
JJefferiesLPLeerink Partners
Sell-side
GSGuggenheim SecuritiesTCTD Cowen
Parties
Target
FFreenome Holdings, Inc.
- Headquarters
- United States
- Ticker
- FRNM
Acquirer
PCPerceptive Capital Solutions Corp
- Headquarters
- United States
- Ticker
- —